甜梦口服液治疗脾肾亏虚型轻度认知损害临床观察

目的观察甜梦口服液治疗脾肾亏虚型轻度认知损害(MCI)的临床疗效。方法将102例MCI患者随机分为治疗组53例和对照组49例。两组均给予胞磷胆碱钠片口服;治疗组加用甜梦口服液,两组均服药8周。两组治疗前后进行简易精神状态检查(MMSE)评分、经颅多普勒(TCD)检查、脾肾亏虚型MCI中医证候(TCMSS)评分;治疗期间观察两组患者依从性及不良反应。结果治疗后两组MMSE较治疗前均提高,治疗组提高更明显(P0.01);两组比较差异显著(P0.05)。治疗组治疗后大脑各动脉峰值平均血流速度(Vm)提高明显(P0.01),与对照组比较差异显著(P0.05)。治疗组脾肾亏虚证候治疗总有效率96.23%,对照组治疗总有效率18.37%,两组比较差异显著(P0.01)。治疗后治疗组TCMSS下降明显(P0.01),与对照组比较差异显著(P0.01)。治疗期间两组患者依从性良好,无不良反应,无脱落病例。结论甜梦口服液可通过降低TCMSS、改善脑血流动力学、提高MMSE评分改善脾肾亏虚型MCI患者认知功能,提高生活质量。

Clinical observation of Sweet Dream Oral Liquid curing deficiency of spleen and kidney style MCI

Objective To observe the clinical effect of Sweet Dream Oral Liquid on the mild cognitive impairment (MCI) patients of spleen and kidney deficiency. Methods A total of 102 patients with MCI were randomly divided into two groups, the treatment group with 53 patients and the control group with 49 patients. Both groups were given Citicoline Sodium Tablets for 8 weeks. The treatment group was given Sweet Dream Oral Liquid extra. Mini-mental state examination (MMSE), Transcranial Doppler (TCD) and Traditional Chinese Medicine Syndrome Score (TCMSS) were performed before and after the treatment. Compliance and adverse reactions for both groups were observed during the treatment. Results MMSE improved after the treatment for both groups; Especially, MMSE of the treatment group improved more obviously (P < 0.01); The difference between the two groups was significant (P < 0.05); For treatment group, the average blood flow velocity (V_m) of the cerebral arteries was increased significantly after the treatment(P < 0.01); Compared with the control group, the difference was obvious (P < 0.05); The total effective rate of the treatment group on spleen and kidney deficiency syndrome was 96.23%. It was 18.37% for the control group. Difference between the two groups was significant (P < 0.01). After the treatment, TCMSS of the treatment group was significantly reduced (P < 0.01); It was a significant difference comparing with the control group (P < 0.01). During the treatment, both groups had a good compliance, no adverse reactions and no shedding patients. Conclusion Sweet Dream Oral Liquid can improve the cognitive function and living quality of the patients with deficiency of spleen and kidney style MCI by reducing TCMSS, improving cerebral hemodynamics and rising MMSE score.